spesolimab对泛发性脓疱型银屑病持续疾病控制的影响:EFFISAYIL 2研究的事后分析
本研究为EFFISAYIL 2试验的事后分析,比较spesolimab 600 mg皮下负荷剂量后每4周300 mg皮下注射与安慰剂对泛发性脓疱型银屑病患者皮肤症状和生存质量负担的持续改善作用。结果显示,截至第48周所有访视,spesolimab组63.3%患者皮肤症状持续改善(安慰剂组29.0%),24.1%患者生存质量负担持续改善(安慰剂组3.2%)。
要点
- spesolimab组63.3%患者皮肤症状持续改善,安慰剂组为29.0%。
- spesolimab组24.1%患者生存质量负担持续改善,安慰剂组为3.2%。
- spesolimab 600 mg皮下负荷后300 mg每4周皮下注射可提供持续改善。
核心结论
- spesolimab 600 mg皮下负荷剂量后300 mg每4周皮下注射相比安慰剂,在显著更高比例的患者中提供皮肤症状和生存质量负担的持续改善。
研究设计与样本
- EFFISAYIL 2试验(NCT04399837)的事后分析,比较spesolimab 600 mg皮下负荷剂量后300 mg每4周皮下注射与安慰剂。
主要发现
- 截至第48周所有访视,spesolimab组63.3%患者皮肤症状持续改善(GPP Physician Global Assessment总分为0或1),安慰剂组为29.0%。
- spesolimab组24.1%患者生存质量负担持续改善(Dermatology Life Quality Index评分为0或1),安慰剂组为3.2%。
关键数值与推荐
- 皮肤症状持续改善定义为截至第48周所有访视GPP Physician Global Assessment总分为0或1。
- 生存质量负担持续改善定义为截至第48周所有访视Dermatology Life Quality Index评分为0或1。
临床怎么用
- 对于泛发性脓疱型银屑病患者,spesolimab 600 mg皮下负荷剂量后300 mg每4周皮下注射可考虑用于实现皮肤症状和生存质量的持续改善。
局限性
- 回顾性、描述性的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL). OBJECTIVE: To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP. METHODS: A post hoc analysis of the EFFISAYIL 2 trial (NCT04399837) was conducted to assess the proportion of patients with sustained improvement of skin symptoms (GPP Physician Global Assessment total score, 0 or 1) and QoL burden (Dermatology Life Quality Index score, 0 or 1) at all visits up to week 48. RESULTS: Among the patients who received spesolimab 600 mg SC LD followed by 300 mg SC q4w, 63.3% had sustained improvement of skin symptoms (vs 29.0%; placebo), and 24.1% had sustained improvement of QoL burden (vs 3.2%; placebo). LIMITATIONS: Retrospective, descriptive, post hoc analysis. CONCLUSION: Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.
引用
- Gordon KB, Augustin M, Barker J, et al. Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. J Am Acad Dermatol. 2025. PMID: 40057892. doi:10.1016/j.jaad.2025.01.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。